241 related articles for article (PubMed ID: 33730843)
1. Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.
Kaburagi T; Yamato G; Shiba N; Yoshida K; Hara Y; Tabuchi K; Shiraishi Y; Ohki K; Sotomatsu M; Arakawa H; Matsuo H; Shimada A; Taki T; Kiyokawa N; Tomizawa D; Horibe K; Miyano S; Taga T; Adachi S; Ogawa S; Hayashi Y
Haematologica; 2022 Mar; 107(3):583-592. PubMed ID: 33730843
[TBL] [Abstract][Full Text] [Related]
2. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.
Chou SC; Tang JL; Hou HA; Chou WC; Hu FC; Chen CY; Yao M; Ko BS; Huang SY; Tsay W; Chen YC; Tien HF
Leuk Res; 2014 Nov; 38(11):1278-84. PubMed ID: 25260824
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract][Full Text] [Related]
6. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
[TBL] [Abstract][Full Text] [Related]
7. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
Balgobind BV; Hollink IH; Arentsen-Peters ST; Zimmermann M; Harbott J; Beverloo HB; von Bergh AR; Cloos J; Kaspers GJ; de Haas V; Zemanova Z; Stary J; Cayuela JM; Baruchel A; Creutzig U; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
Haematologica; 2011 Oct; 96(10):1478-87. PubMed ID: 21791472
[TBL] [Abstract][Full Text] [Related]
9. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A; Taki T; Koga D; Tabuchi K; Tawa A; Hanada R; Tsuchida M; Horibe K; Tsukimoto I; Adachi S; Kojima S; Hayashi Y
Int J Hematol; 2012 Oct; 96(4):469-76. PubMed ID: 22915059
[TBL] [Abstract][Full Text] [Related]
10. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
11. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
12. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
13. Impact of
Mustafa Ali MK; Williams MT; Corley EM; AlKaabba F; Niyongere S
Leuk Lymphoma; 2023 May; 64(5):962-971. PubMed ID: 37042657
[TBL] [Abstract][Full Text] [Related]
14. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
15. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database.
Xu J; Zhang Y; Hu J; Ren Y; Wang H
Hematology; 2020 Dec; 25(1):79-84. PubMed ID: 32019476
[No Abstract] [Full Text] [Related]
17. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
18. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract][Full Text] [Related]
19. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia.
Xu LH; Fang JP; Liu YC; Jones AI; Chai L
Blood Cancer J; 2020 Jan; 10(1):1. PubMed ID: 31915364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]